1. MICROBIOLOGIC SPECTRA AND THEIR ANTIBIOTIC SUSCEPTIBILITY PATTERNS IN TYPE 2 DIABETIC PATIENTS WITH URINARY TRACT INFECTIONS (UTIS) - A HOSPITAL BASED STUDY.
- Author
-
Badshah, Aliena, Khan, Arooba, Mohammad, Wazir, Zaman, Rabia, Khan, Zahid Ullah, and Haider, Iqbal
- Subjects
URINARY tract infections ,PEOPLE with diabetes ,PATIENTS ,ANTIBIOTICS ,AZTREONAM - Abstract
Objectives: To determine the microbiologic spectra and their antibiotic susceptibility patterns in type 2 diabetic patients with UTIs Materials and Methods: This descriptive cross-sectional study was conducted in the Department of Medicine, Khyber Teaching Hospital, Peshawar from 1
st July 2021 to 31st December 2021. Type 2 Diabetic patients with urinary tract infections were recruited in the study. Their urine cultures for sensitivities were carried out. The frequency of positive urine culture was stratified among age and gender to see the effect modifications. Antibiotic sensitivity and resistance patterns were stratified among male and female diabetic patients. Results: Out of 150 patients, 125 were females and 25 were males. Twenty-seven (27) patients (24.3%) had positive urine cultures, out of whom 19 (70.4%) were females, and 8 (29.6%) were males. The most common organism found in females was E.coli (42%). Among male patients with positive urine cultures, E.coli was the most common organism isolated in 5 (62.51%). Cefixime had the highest resistance, with 21(77.8%) of 25 culture-positive patients resistant to it. All the patients with positive urine cultures were sensitive to piperacillin/tazobactam, Meropenem, Doripenem, Cefepime, Aztreonam, and Tigecycline. Conclusion: Diabetic females are more prone to UTIs with an increased prevalence of positive urine cultures as compared to diabetic men. The most common isolate was E.coli. The highest antimicrobial resistance was reported for Cefixime. All patients were sensitive to Meropenem, Tazobactam/Piperacillin, Aztreonam, Tigecycline, Doripenem, and Cefepime. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF